Prime MedicinePRME +8.03%25 EV-to-FCF is -3.77 as of Jun. 28, 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 336 Biotechnology companies, Prime Medicine ranks worse than 297618.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Prime Medicine's Enterprise Value is $598.53 Mil.
Prime Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-158.74 Mil. Therefore, Prime Medicine's EV-to-FCF for today is -3.77.
The historical rank and industry rank for Prime Medicine's EV-to-FCF or its related term are showing as below:
PRME'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.99 Med: -2.59 Max: -0.65
Current: -3.77
During the past 6 years, the highest EV-to-FCF of Prime Medicine was -0.65. The lowest was -7.99. And the median was -2.59.
PRME's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs PRME: -3.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prime Medicine's PE Ratio (TTM) for today is calculated as:
Prime Medicine's share price for today is $3.43.
Prime Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Prime Medicine EV-to-FCF Related Terms
Prime Medicine EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Prime Medicine's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Prime Medicine's EV-to-FCF falls into.
Prime Medicine's current Enterprise Value is $598.53 Mil.
Prime Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-158.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (PRME) has a EV-to-FCF of -3.77 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #999999 out of 336 companies in the Biotechnology industry.
Is Prime Medicine's EV-to-FCF too high?
Prime Medicine's current EV-to-FCF is -3.77. Based on the distribution chart, Prime Medicine ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's EV-to-FCF compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #999999 out of 336 companies for EV-to-FCF. This places Prime Medicine in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prime Medicine and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current EV-to-FCF is -3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current EV-to-FCF of -3.77. The current EV-to-FCF is -3.77. Prime Medicine's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Prime Medicine (PRME), the current EV-to-FCF is -3.77 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
